Navigation Links
Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
Date:9/18/2007

pon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward- looking statements include, but are not limited to, statements about the successful implementation of Pharmacopeia's strategic plans, Pharmacopeia's plans to develop PS433540, a product candidate from its DARA program, Pharmacopeia's Phase 1 and Phase 2 clinical studies with respect to PS433540, including timing and expected outcomes of such studies, Pharmacopeia's estimates of the market opportunities for its product candidates, including PS433540, Pharmacopeia's ability to successfully perform under its collaborations with Cephalon, GlaxoSmithKline, Organon and Wyeth, Pharmacopeia's ability to build its pipeline of novel drug candidates through its own internally-funded drug discovery programs, third party collaborations and in-licensing, Pharmacopeia's ability to raise additional capital, Pharmacopeia's expectations concerning the development priorities of its collaborators, their ability to successfully develop compounds and its receipt of milestones and royalties from the collaborations, Pharmacopeia's anticipated operating results, financial condition, liquidity and capital resources, Pharmacopeia's expectations concerning the legal protections afforded by U.S. and international patent law, Pharmacopeia's ability to pursue the development of new compounds and other business matters without infringing the patent rights of others, additional competition, and changes in economic conditions.

Further information about these and other relevant risks and uncertainties may be found in Pharmacopeia's Reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Pharmacopeia urges you to carefully review and consider the disclosures found in its filings which are available in the SEC EDGAR database at
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  CVS Caremark Corporation (NYSE: ... call on Tuesday, August 5, 2014, at 8:30 a.m. ... quarter 2014 financial results. An audio webcast ... the Investor Relations portion of the CVS Caremark website ... http://info.cvscaremark.com/investors . This webcast will be archived and ...
(Date:7/25/2014)... , July 25, 2014 Cardinal Health will ... pharmacies as winners of its prestigious Independent Pharmacy Best ... , one of the nation,s largest gatherings of independent ... – family-owned pharmacies from Ohio , ... – were selected for implementing exceptionally creative ...
(Date:7/25/2014)... , July 25, 2014 According ... Research "Global and China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, ... Size, Share, Growth, Trends and Forecast (Value and Volume), ... at USD 19.99 billion in 2012 and is expected ... to 2019 to reach USD 32.24 billion in 2019. ...
Breaking Medicine Technology:Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 2Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 3Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 4Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 5Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 6Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4
... Medical Technologies, Inc. (the "Company") (Nasdaq: CMED ... today announced the filing of its annual report on ... 2011 with the U.S. Securities and Exchange Commission (the ... financial statements for the fiscal year ended March 31, ...
... July 18, 2011 Scientists at Osel Inc ... have developed a new way to prevent HIV infection ... bacteria to block viral transmission. Bioengineered bacteria introduced into ... the transmission of simian HIV (SHIV) by nearly two ...
Cached Medicine Technology:China Medical Technologies Announces the Filing of its Annual Report on Form 20-F for the Fiscal Year Ended March 31, 2011 with the SEC 2Scientists Use Live Bacteria to Fight HIV 2Scientists Use Live Bacteria to Fight HIV 3
(Date:7/25/2014)... Port Washington, NY (PRWEB) July 25, 2014 ... to protecting the rights of consumers comments on a ... the widow of a smoker $23.6 billion in punitive ... which manufactures Kool brand cigarettes. The case is Cynthia ... in 2008 in the Florida First Circuit Court, Escambia ...
(Date:7/25/2014)... nearly 27,000 older adults on five continents found that ... on a simple test that measures how fast people ... tested positive for pre-dementia were twice as likely as ... led by scientists at Albert Einstein College of ... Center , was published online on July 16, 2014 ...
(Date:7/25/2014)... AZ (PRWEB) July 25, 2014 Hastings ... offering discount attorney’s fees with regard to personal ... Hastings provide a wide range of legal services for ... the negligence of another individual or corporation. Free initial ... determining the validity of a potential personal injury ...
(Date:7/25/2014)... 2014 As thousands of transvaginal mesh ... Bernstein Liebhard LLP notes that the Food & Drug ... advocacy group, Public Citizen, to order a global recall ... May 1, 2014, and released to the public last ... a ban on the marketing of all surgical mesh ...
(Date:7/25/2014)... (HealthDay News) -- Babies seem to learn even before ... time women are 34 weeks pregnant, their unborn babies ... reciting a familiar nursery rhyme, the researchers report. ... stimulation in the developing fetus," Charlene Krueger, nursing researcher ... of Nursing, said in a university news release. "This ...
Breaking Medicine News(10 mins):Health News:A Florida Jury Awards Widow More Than $23 Billion in Punitive Damages in a Lawsuit Brought Against Tobacco Maker, R.J. Reynolds, Parker Waichman LLP Comments 2Health News:A Florida Jury Awards Widow More Than $23 Billion in Punitive Damages in a Lawsuit Brought Against Tobacco Maker, R.J. Reynolds, Parker Waichman LLP Comments 3Health News:Slow walking speed and memory complaints can predict dementia 2Health News:Slow walking speed and memory complaints can predict dementia 3Health News:Slow walking speed and memory complaints can predict dementia 4Health News:Hastings and Hastings Announces Complimentary Consultation Services 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 3Health News:Transvaginal Mesh Lawsuit News: FDA Rejects Petition Seeking Ban and Global Recall of All Transvaginal Mesh Products, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: FDA Rejects Petition Seeking Ban and Global Recall of All Transvaginal Mesh Products, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit News: FDA Rejects Petition Seeking Ban and Global Recall of All Transvaginal Mesh Products, Bernstein Liebhard LLP Reports 4Health News:Rhymes Reveal Evidence of Learning in the Womb 2
... A number of biological, societal, and health carerelated issues ... with kidney disease, according to two articles appearing in ... American Society Nephrology (JASN). The articles indicate that immediate ... needed to provide better health care for affected Americans. ...
... Next ... 14 Years, ANCHORAGE, ... successfully transitioned all of its rural,telecommunication services last night to the Galaxy ... rural Alaska for the next 14 years., "The success of last ...
... Utilize Strategic Intelligence and Competitive Analysis, from Thomson Reuters to ... on Medical Research and the U.S. Generics ... ... June 4 Thomson Reuters, the,world,s leading source of intelligent information ...
... Company,s DSU Products offer biologically safe water through point-of-use ... ... June 3 Nephros, Inc., a medical,device company, announced today ... the Association for Professionals in Infection,Control and Epidemiology (APIC) conference ...
... Trains Interventional Cardiologists to Stop Strokes, WASHINGTON, ... stroke, every,second counts in saving brain tissue and ... are learning to capture and,remove blood clots in ... treatments used to stop a heart attack. To ...
... 3 Most of us take sleeping safely ... ever slept in a bunk bed, the,safe part ... thing., Listen to this report from Nationwide ... can access video, audio, text, graphics and,photos for ...
Cached Medicine News:Health News:Racial disparities in the outcomes of patients with chronic kidney disease abound 2Health News:Racial disparities in the outcomes of patients with chronic kidney disease abound 3Health News:GCI Successfully Transitions All Traffic to Galaxy 18 Satellite 2Health News:The Scientific Business of Thomson Reuters Publishes Pharma Matters - a Series of Reviews Covering Various Aspects of the Pharmaceutical Pipeline 2Health News:The Scientific Business of Thomson Reuters Publishes Pharma Matters - a Series of Reviews Covering Various Aspects of the Pharmaceutical Pipeline 3Health News:Nephros Exhibiting at Denver, Colorado APIC Conference June 15th-19th 2Health News:Nephros Exhibiting at Denver, Colorado APIC Conference June 15th-19th 3Health News:Nephros Exhibiting at Denver, Colorado APIC Conference June 15th-19th 4Health News:Unique Simulation Training Course Ushers in New Era of Stroke Intervention 2Health News:Unique Simulation Training Course Ushers in New Era of Stroke Intervention 3Health News:Unique Simulation Training Course Ushers in New Era of Stroke Intervention 4
Body Suit w/Bra above knee...
Gynecomastia Vest...
Male Compression Vest, Front Closure...
Female Mini-VEST, Front Closure, X-Firm...
Medicine Products: